The company says it is in advanced discussions to settle the investigation.
The charge amounts to $1.29 per share.
Zyprexa has been Lilly's top-selling drug for years but also has been subject to reams of litigation. Earlier this month, Lilly announced a separate $62 million settlement with 32 states and Washington, D.C., over marketing practices.
(Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)